J. Mestan - Concepedia

Author

J. Mestan

Also Known As

J Mestan, J. Mestan, Juergan Mestan, Mestan, J.

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

J. Mestan is an author at Novartis (Switzerland) specializing in pharmacology, medicine, and tumor biology.

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	901
2	Cell Biology	3	3	883
3	Natural Sciences	1	1	18
4	Biomolecular Engineering	1	1	18
5	Immunology	1	1	846

J. Mestan

Publications

Citations

H-Index

Page 1

	Year	Citations
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. J M Wood, Guido Bold, Elisabeth Buchdunger, PubMed ImmunologyOral AdministrationPharmacotherapyTumor BiologyAngiogenesis	2000	846
Vascular Endothelial Growth Factor (VEGF) Receptor-2 Antagonists Inhibit VEGF- and Basic Fibroblast Growth Factor-Induced Angiogenesis in Vivo and in Vitro JC Tille, J M Wood, Stefano J. Mandriota, Journal of Pharmacology and Experimental Therapeutics	2001	127
Differential phosphoprofiles of EGF and EGFR kinase inhibitor-treated human tumor cells and mouse xenografts David R. Stover, Jennifer Caldwell, Jarrod A. Marto, Clinical Proteomics Differential PhosphoprofilesMedicineReceptor Tyrosine KinaseMouse XenograftsTumor Targeting	2004	27
CGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridylmethyl)phthalazines as inhibitors of VEGF- and bFGF-induced angiogenesis Guido Bold, Joerg Frei, Pascal Furet, Drugs of the Future Medicinal ChemistryAngiogenesisMedicineNatural SciencesBfgf-induced Angiogenesis	2002	18
NVP-TAE226, a potent dual FAK/IGF-IR kinase inhibitor, prevents breast cancer metastasis in vivo Ei Kawahara, Osamu Ohmori, K. Nonomura, Journal of Clinical Oncology Breast OncologyCancer MetastasisCancer BiologyTumor BiologyReceptor Tyrosine Kinase	2006	10

Page 1